Eloxx reprices CEO Sumit Aggarwal's options to $0.90 from $37.47 per share

Eloxx Pharmaceuticals, Inc.

Option repricing approved by Board on March 25, 2024 for CEO Sumit Aggarwal.
Exercise price reduced to $0.90 per share (closing price on March 25, 2024).
Affects 196,880 shares previously exercisable at weighted average $37.47.
All outstanding eligible options under 2018 Equity Incentive Plan included.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.